Bristol-Myers receives unconditional approval to buy Celgene in Brazil
MLex Summary: Bristol-Myers Squibb's planned $74 billion acquisition of rival drugmaker Celgene was cleared, without conditions, by the Brazilian competition authority, according to a statement in the case file. Bristol-Myers is listed...To view the full article, register now.
Already a subscriber? Click here to view full article